Discontinued — last reported Q4 '21
Business Segments · Payments for Restructuring
Covance Drug Development — Payments for Restructuring
Labcorp Holdings Covance Drug Development — Payments for Restructuring remained flat by 0.0% to -$4.33M in Q4 2021 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryLiquidity
SignalLower is better
VolatilityModerate
First reportedQ1 2020
Last reportedQ4 2021Feb 25, 2022
Rolls up toPayments for Restructuring
How to read this metric
High cash outflows indicate the active execution phase of a restructuring program.
Detailed definition
The actual cash outflow related to the execution of restructuring plans, such as severance payments or lease exit costs,...
Peer comparison
Used to reconcile cash flow statements with reported restructuring expenses.
Metric ID:
lh_segment_covance_drug_development_payments_for_restructuringHistorical Data
1 years
| FY'21 | |
|---|---|
| Value | -$17.30M |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's covance drug development — payments for restructuring?
- Labcorp Holdings (LH) reported covance drug development — payments for restructuring of -$4.33M in Q4 2021.
- What does covance drug development — payments for restructuring mean?
- Actual cash spent on restructuring the drug development segment.